Cytori Therapeutics Announces Company Presentation the 2012 Stem Cell Meeting on the Mesa's Investor
Cytori Therapeutics Announces Company Presentation the 2012 Stem Cell Meeting on the Mesa's Investor and Partnering Forum on October 30
The following are specific details regarding Cytori's presentation at the conference:
|Date:||October 30th, 2012|
|Location:||Sanford Consortium for Regenerative Medicine Building Auditorium, 2nd Floor Terrace|
|2880 Torrey Pines Scenic Drive, La Jolla, California|
The presentation will be recorded and will be available on the Webcasts page of the Cytori's investor relations site the week following the conference.
The Investor and Partnering Forum is being organized by the Alliance for Regenerative Medicine (ARM) and the California Institute for Regenerative Medicine to profile the industry's most exciting technologies.
Cytori Therapeutics, Inc. is developing cell therapies based on autologous adipose-derived regenerative cells (ADRCs) to treat cardiovascular disease and repair soft tissue defects. Our scientific data suggest ADRCs improve blood flow, moderate the immune response and keep tissue at risk of dying alive. As a result, we believe these cells can be applied across multiple "ischemic" conditions. These therapies are made available to the physician and patient at the point-of-care by Cytori's proprietary technologies and products, including the Celution® system product family. www.cytori.com
Cytori Therapeutics, Inc.
Megan McCormick, +1-858-875-5279
KEYWORDS: United States North America California
The article Cytori Therapeutics Announces Company Presentation the 2012 Stem Cell Meeting on the Mesa's Investor and Partnering Forum on October 30 originally appeared on Fool.com.Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.